Travere Therapeutics, Inc.

TVTX

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001438533

B

second fifth of 305 graded peers in healthcare

rank 85 of 305; percentile 27.6; sampling error 2.8 points; lower is stronger

A B C D E


B, the elk



Scoreboard


Profitability	B percentile 28.1
Solvency	C/D percentile 57.4
Growth and financing	B percentile 36.8
Reliability	0.91 AUC filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$591M to $2.67B assets total assets $605.2M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: distress, fortress balance sheet
Inputs computable	8 of 13
Graded from	filings received through Feb 19, 2026 274 days before the rescan; latest periodic filing 10-Q received Nov 2, 2026
Last close	$48.30 2026-11-19; market equity $4.6B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 19, 2026

Those statements in the following discussion that are not historical in nature should be considered forward-looking statements that are inherently uncertain. Actual results and the timing of the events may differ materially from those contained in these forward-looking statements due to a number of factors, including those discussed in the "Cautionary Statement Regarding Forward-Looking Statements" and "Risk Factors" set forth elsewhere in this Annual Report. We are a biopharmaceutical company headquartered in San Diego, California, focused on identifying, developing and delivering life-changing therapies to people living with rare kidney and metabolic diseases.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight


Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 28.1						
Gross profitability	79.4%	32.8%		8.7	346	2025-12-31
Return on invested capital	not computable	9.6%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing						
Accruals ratio	(10.6%)	(6.7%)		38.7	756	2025-12-31
Gross margin stability, five years	2.0 pts	2.8 pts		36.9	237	2025-12-31
Solvency, sleeve percentile 57.4						
Altman Z double-prime	(5.38)	0.31		54.1	705	2025-12-31
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	not computable	(3.61x)				
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31						
Current ratio	2.74x	2.68x		60.6	781	2025-12-31
Growth and financing, sleeve percentile 36.8						
Revenue growth, three-year compound	64.9%	9.6%		8.5	400	2025-12-31
Free cash flow growth, three-year compound	not computable	11.1%				
current FCF must be positive and base FCF must exceed $100,000						
Reinvestment rate	not computable	33.9%				
pretax income must exceed the validity floor and imply a 0%-100% tax rate						
Asset growth, three years	(3.5%)	3.2%		60.1	663	2025-12-31
Net share issuance, one year	3.9%	1.6%		41.8	625	2026-02-13

Among 305 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
80	Phibro Animal Health Corp. (PAHC)	26.0	B	
81	Mannatech Inc. (MTEX)	26.3	B	late filer, fortress balance sheet
82	Agios Pharmaceuticals, Inc. (AGIO)	26.6	B	short runway
83	Sensus Healthcare, Inc. (SRTS)	27.0	B	
84	Alphatec Holdings, Inc. (ATEC)	27.3	B	
85	Travere Therapeutics, Inc. (TVTX)	27.6	B	
86	Tela Bio, Inc. (TELA)	28.0	B	fortress balance sheet
87	Cytokinetics Inc. (CYTK)	28.3	B	short runway
88	Myriad Genetics Inc. (MYGN)	28.6	B	fortress balance sheet
89	Agape ATP Corp. (ATPC)	28.9	B	late filer
90	Healthcare Services Group Inc. (HCSG)	29.3	B	

What the price implies

at the 2026-11-19 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	67.5%	(1.7%)	85
Distance from 52-week high	(28.5%)	(31.7%)	53
EBIT to enterprise value	(1.4%)	0.5%	44
Free cash flow yield	(6.1%)	0.6%	32
Book value to price	0.00	0.29	11

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Sales to price	0.11	0.37	20
Composite equity issuance, five years	46.6%	13.5%	73
Relative strength against the sector, log excess return	0.34	(0.19)	85
Twelve-month failure probability, CHS model	not computable	0.06%	

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$123.5M
Operating cash flow, four quarters	$176.6M
Months of runway	not finite
Days since last periodic filing	18 (10-Q received Nov 2, 2026)
Median daily dollar volume, 63 sessions	$89.9M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$490.7M	2025-12-31	2026-02-19	10-K	26-000014
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$10.3M	2025-12-31	2026-02-19	10-K	26-000014
3	assets	us-gaap:Assets	$605.2M	2025-12-31	2026-02-19	10-K	26-000014
4	net income	us-gaap:NetIncomeLoss	-$25.5M	2025-12-31	2026-02-19	10-K	26-000014
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$37.8M	2025-12-31	2026-02-19	10-K	26-000014
6	assets	us-gaap:Assets	$594.1M	2024-12-31	2026-02-19	10-K	26-000014
7	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$233.2M	2024-12-31	2026-02-19	10-K	26-000014
8	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$7.7M	2024-12-31	2026-02-19	10-K	26-000014
9	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$145.2M	2023-12-31	2026-02-19	10-K	26-000014
10	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$11.4M	2023-12-31	2026-02-19	10-K	26-000014
11	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$109.5M	2022-12-31	2025-02-21	10-K	25-000010
12	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$4.4M	2022-12-31	2025-02-21	10-K	25-000010
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$131.8M	2021-12-31	2024-02-20	10-K	24-000005
14	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$3.8M	2021-12-31	2024-02-20	10-K	24-000005
15	current assets	us-gaap:AssetsCurrent	$437.6M	2025-12-31	2026-02-19	10-K	26-000014
16	current liabilities	us-gaap:LiabilitiesCurrent	$159.9M	2025-12-31	2026-02-19	10-K	26-000014
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$1.5B	2025-12-31	2026-02-19	10-K	26-000014
18	operating income	us-gaap:OperatingIncomeLoss	-$62.8M	2025-12-31	2026-02-19	10-K	26-000014
19	book equity	us-gaap:StockholdersEquity	$114.8M	2025-12-31	2026-02-19	10-K	26-000014
20	liabilities	us-gaap:Liabilities	$490.4M	2025-12-31	2026-02-19	10-K	26-000014
21	operating income	us-gaap:OperatingIncomeLoss	-$388.1M	2023-12-31	2026-02-19	10-K	26-000014
22	interest expense	us-gaap:InterestExpense	$11.3M	2023-12-31	2024-02-20	10-K	24-000005
23	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$280.0M	2023-12-31	2026-02-19	10-K	26-000014
24	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$668,000	2023-12-31	2024-02-20	10-K	24-000005
25	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$186.3M	2022-12-31	2025-02-21	10-K	25-000010
26	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$191,000	2022-12-31	2024-02-20	10-K	24-000005

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

27	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$14.8M	2021-12-31	2024-02-20	10-K	24-000005
28	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$5.1M	2021-12-31	2024-02-20	10-K	24-000005
29	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$42.7M	2020-12-31	2023-02-23	10-K	23-000008
30	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$6.8M	2020-12-31	2023-02-23	10-K	23-000008
31	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$38.5M	2023-12-31	2026-02-19	10-K	26-000014
32	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$376.1M	2023-12-31	2026-02-19	10-K	26-000014
33	income tax	us-gaap:IncomeTaxExpenseBenefit	$223,000	2023-12-31	2026-02-19	10-K	26-000014
34	current assets	us-gaap:AssetsCurrent	$616.8M	2023-12-31	2025-02-21	10-K	25-000010
35	current liabilities	us-gaap:LiabilitiesCurrent	$177.9M	2023-12-31	2025-02-21	10-K	25-000010
36	current assets	us-gaap:AssetsCurrent	$486.4M	2022-12-31	2024-02-20	10-K	24-000005
37	current liabilities	us-gaap:LiabilitiesCurrent	$142.2M	2022-12-31	2024-02-20	10-K	24-000005
38	assets	us-gaap:Assets	$788.9M	2023-12-31	2025-02-21	10-K	25-000010
39	assets	us-gaap:Assets	$672.6M	2022-12-31	2024-02-20	10-K	24-000005
40	shares outstanding	dei:EntityCommonStockSharesOutstanding	92,241,550	2026-02-13	2026-02-19	10-K	26-000014
41	shares outstanding	dei:EntityCommonStockSharesOutstanding	88,739,826	2025-02-18	2025-02-21	10-K	25-000010

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.